{
    "clinical_study": {
        "@rank": "141189", 
        "arm_group": [
            {
                "arm_group_label": "Insulin glargine new formulation (test T formulation)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily for 6 days"
            }, 
            {
                "arm_group_label": "Insulin glargine new formulation (reference R formulation)", 
                "arm_group_type": "Experimental", 
                "description": "Once daily for 6 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To demonstrate equivalence in exposure to insulin glargine given as test formulation T and\n      reference formulation R in steady state conditions after 6 once-daily subcutaneous (SC)\n      doses\n\n      Secondary Objective:\n\n        -  To assess relative Pharmacodynamic activity of the insulin glargine test formulation T\n           to the insulin glargine reference formulation R in steady state conditions after 6\n           once-daily SC doses\n\n        -  To assess the safety and tolerability of the test and reference  formulations of two\n           new insulin glargine formulations"
        }, 
        "brief_title": "Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total study duration per subject: 29 to 64 days including screening visit\n\n      Duration of each part of the study for one subject:\n\n        -  Screening: 3 to 21 days before 1st dosing (Day -21 to Day -3)\n\n        -  Treatment Period 1 and 2: 8 days (dosing on 6 days)\n\n        -  Washout between last/1st dosing days of the treatment periods: 7-21 days\n           (preferentially 7 days) End-of-Study Visit: 7-10 days after last dosing"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n          -  Male or female subjects, between 18 and 64 years of age, inclusive, with diabetes\n             mellitus type 1 for more than one year\n\n          -  Total insulin dose of < 1.2 U/kg/day\n\n          -  Minimum usual basal insulin dose \u2265 0.2 U/kg/day\n\n          -  Body weight between 50.0 kg and 110.0 kg, Body Mass Index between 18.5 and 30.0 kg/m2\n             inclusive\n\n          -  Fasting negative serum C-peptide (< 0.3 nmol/L)\n\n          -  Glycohemoglobin (HbA1c) \u2264 75 mmol/mol [\u2264 9.0%]\n\n          -  Stable insulin regimen for at least 2 months prior to inclusion in study\n\n          -  Certified as otherwise healthy for Type-1 Diabetes mellitus patient\n\n          -  Laboratory parameters within the normal range\n\n          -  Women of childbearing potential with negative pregnancy test and use of a highly\n             effective contraceptive method or women with confirmed postmenopausal status\n\n        Exclusion criteria:\n\n          -  Any history or presence of clinically relevant cardiovascular, pulmonary,\n             gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1),\n             hematological, neurological, psychiatric, systemic (affecting the body as a whole),\n             ocular, gynecologic (if female), or infectious disease; any acute infectious disease\n             or signs of acute illness.\n\n          -  More than one episode of severe hypoglycemia with seizure, coma or requiring\n             assistance of another person during the past 6 months\n\n          -  Frequent severe headaches and / or migraine, recurrent nausea and / or vomiting (more\n             than twice a month)\n\n          -  Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic\n             postural hypotension defined by a decrease in systolic blood pressure equal to or\n             greater than 20 mmHg within three minutes when changing from the supine to the\n             standing position\n\n          -  Presence or history of a drug allergy or clinically significant allergic disease\n             according to the Investigator's judgment\n\n          -  Likelihood of requiring treatment during the study period with drugs not permitted by\n             the clinical study protocol\n\n          -  Presence or history of drug or alcohol abuse (alcohol consumption > 40 grams / day)\n\n          -  If female, pregnancy (defined as positive Beta Human Chorionic Gonadotropin test),\n             breast-feeding\n\n          -  Known hypersensitivity to insulin glargine or excipients of the study drug\n\n          -  Any history or presence of deep leg vein thrombosis or a frequent appearance of deep\n             leg vein thrombosis in first degree relatives (parents, siblings or children)\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838083", 
            "org_study_id": "PKD13560", 
            "secondary_id": [
                "2012-005777-31", 
                "U1111-1139-3755"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Insulin glargine new formulation (test T formulation)", 
                "Insulin glargine new formulation (reference R formulation)"
            ], 
            "description": "Pharmaceutical form: solution Route of administration: subcutaneous", 
            "intervention_name": "Insulin glargine new formulation HOE901", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }, 
                "name": "Investigational Site Number 276001"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two New Insulin Glargine Formulations Using the Euglycemic Clamp Technique in Subjects With Type 1 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6", 
            "safety_issue": "No", 
            "time_frame": "24-hours (D6 to D7)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838083"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum insulin concentration (INS-Cmax)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Time to INS-Cmax (INS-tmax)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Time to reach 50% of INS-AUC0-24 (T50%-INS-AUC0-24)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Area under the body-weight-standardized Glucose Infusion Rate (GIR) within 24 hours (GIR-AUC0-24h) after dosing on Day 6 during the clamp", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Maximum smoothed body weight standardized glucose infusion rate (GIRmax)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Time to GIRmax (GIR-Tmax)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Time to reach at least 50% of GIR-AUC0-24 (T50%-GIR-AUC0-24)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different prespecified blood glucose levels)", 
                "safety_issue": "No", 
                "time_frame": "24-hours (D6 to D7)"
            }, 
            {
                "measure": "Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 9 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}